References

European Society of Cardiology: cardiovascular disease statistics 2025

10.1093/eurheartj/ehag345 · 2026 · External reference

Pharmacogenetics to guide cardiovascular drug therapy

10.1038/s41569-021-00549-w · 2021 · External reference

Unresolved reference

External reference

Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population

10.1038/s41397-024-00350-1 · 2024 · External reference

Pharmacogenomics in stroke and cardiovascular disease: state of the art

10.1161/strokeaha.122.037717 · 2023 · External reference

Pharmacogenomics of statins and familial hypercholesterolemia

10.1097/mol.0000000000000746 · 2021 · External reference

Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy

10.1002/cpt.3351 · 2024 · External reference

Unresolved reference

External reference

Pharmacogenomics in practice: a review and implementation guide

10.3389/fphar.2023.1189976 · 2023 · External reference

Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

10.1093/ehjcvp/pvab063 · 2022 · External reference

Pharmacogenomics in the UK National Health Service: opportunities and challenges

10.2217/pgs-2020-0091 · 2020 · External reference

Pharmacogenomics: an evolving clinical tool for precision medicine

10.3949/ccjm.87a.19073 · 2020 · External reference

Pharmacogenomics in the era of personalized medicine

10.5694/mja2.51759 · 2022 · External reference